[go: up one dir, main page]

MA34378B1 - Cristal de composé amide - Google Patents

Cristal de composé amide

Info

Publication number
MA34378B1
MA34378B1 MA35560A MA35560A MA34378B1 MA 34378 B1 MA34378 B1 MA 34378B1 MA 35560 A MA35560 A MA 35560A MA 35560 A MA35560 A MA 35560A MA 34378 B1 MA34378 B1 MA 34378B1
Authority
MA
Morocco
Prior art keywords
crystal
benzoimidazole
ylcarbonyl
methoxybutyl
morpholin
Prior art date
Application number
MA35560A
Other languages
English (en)
Inventor
Masato Kitayama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA34378B1 publication Critical patent/MA34378B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN CRISTAL DE CHLORHYDRATE 1-(4-MÉTHOXYBUTYLE)-N-(2-MÉTHYLPROPYLE)-N-[(3S, 5R)-5-(MORPHOLINE-4-YLCARBONYL)PIPÉRIDINE-3-YLE]-1H-BENZOIMIDAZOLE-2-CARBOXAMIDE QUI POSSÈDE UNE EXCELLENTE ACTIVITÉ INHIBITRICE DE LA RÉNINE, ET EST UTILE EN TANT QU'AGENT PRÉVENTIF OU THÉRAPEUTIQUE POUR DES TYPES DE DYSFONCTIONNEMENT D'ORGANES ET ANALOGUE DUS À UNE PRESSION ARTÉRIELLE ÉLEVÉE ET UNE HYPERTENSION. LEDIT CRISTAL DE CHLORHYDRATE 1-(4-MÉTHOXYBUTYLE)-N-(2-MÉTHYLPROPYLE)-N-[(3S, 5R)-5-(MORPHOLINE-4-YLCARBONYL)PIPÉRIDINE-3-YLE]-1H-BENZOIMIDAZOLE-2-CARBOXAMIDE PRÉSENTE UN DIAGRAMME DE DIFFRACTION DES RAYONS X SUR POUDRE, LES CONSTANTES DU RÉSEAU (D) DE LA DIFFRACTION DES RAYONS X SUR POUDRE AFFICHANT DES PICS CARACTÉRISTIQUES QUI APPARAISSENT AUTOUR DE 26,43 ± 0,2, 7,62 ± 0,2, ET 4,32 ± 0 2 ANGSTRÖMS.
MA35560A 2010-06-16 2011-06-16 Cristal de composé amide MA34378B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010137194 2010-06-16
PCT/JP2011/063735 WO2011158880A1 (fr) 2010-06-16 2011-06-15 Cristal de composé amide

Publications (1)

Publication Number Publication Date
MA34378B1 true MA34378B1 (fr) 2013-07-03

Family

ID=45348277

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35560A MA34378B1 (fr) 2010-06-16 2011-06-16 Cristal de composé amide

Country Status (27)

Country Link
US (1) US9018374B2 (fr)
EP (1) EP2583967B1 (fr)
JP (1) JP5782438B2 (fr)
KR (1) KR20130119903A (fr)
CN (1) CN103068816B (fr)
AU (1) AU2011266099B2 (fr)
BR (1) BR112012032055B8 (fr)
CA (1) CA2802483C (fr)
CL (1) CL2012003526A1 (fr)
CO (1) CO6670573A2 (fr)
DO (1) DOP2012000313A (fr)
EA (1) EA022094B1 (fr)
EC (1) ECSP13012392A (fr)
ES (1) ES2524896T3 (fr)
GE (1) GEP20146195B (fr)
IL (1) IL223562A (fr)
MA (1) MA34378B1 (fr)
MX (1) MX2012014828A (fr)
MY (1) MY163927A (fr)
PE (1) PE20130283A1 (fr)
PH (1) PH12012502468A1 (fr)
SG (1) SG186223A1 (fr)
TN (1) TN2012000589A1 (fr)
TW (1) TWI511967B (fr)
UA (1) UA108888C2 (fr)
WO (1) WO2011158880A1 (fr)
ZA (1) ZA201300065B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781226A (zh) * 2012-02-14 2015-07-15 陶氏环球技术有限责任公司 非离子型表面活性剂组合物
US20150011549A1 (en) * 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
CN103831159B (zh) * 2014-01-20 2016-04-13 华润赛科药业有限责任公司 一种阿齐沙坦微粉化方法
EP3130581A4 (fr) * 2014-04-10 2017-11-22 Takeda Pharmaceutical Company Limited Procédé de production d'un composé hétérocyclique
GB2542876B (en) * 2015-04-20 2019-10-23 Johnson Matthey Plc Structure Directing Agent
CN107595842A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种药物复方制剂及在制备治疗高血压合并冠心病的药物中的用途
CN107595853A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种用于治疗高血压合并冠心病的药物组合物及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
CA2505322A1 (fr) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Agent de controle de la fonction recepteur
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CN100343248C (zh) * 2003-04-15 2007-10-17 安斯泰来制药株式会社 溴化物及其晶体
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
WO2004106276A1 (fr) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited Compose cyclique condense
EP1641779A1 (fr) 2003-06-18 2006-04-05 AstraZeneca AB Derives de 5,6-diaryl-pyrazine substitués en position 2 comme modulateurs cb1
WO2005030740A1 (fr) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited Derive thiazoline et utilisation
WO2005058823A1 (fr) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Derives d'uree, processus de production correspondant et utilisation
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (fr) 2004-03-15 2008-02-13 Takeda Pharmaceutical Derive de l'acide aminophnylpropano
WO2005095338A1 (fr) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Dérivés de l’acide alkoxyphénylpropanoïque
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JP5044398B2 (ja) 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
PE20070338A1 (es) 2005-08-10 2007-04-16 Takeda Pharmaceutical Derivados heterociclicos como agentes terapeuticos para diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN102731451B (zh) 2006-06-27 2015-07-29 武田药品工业株式会社 稠环化合物
WO2008047821A1 (fr) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
JP5260507B2 (ja) 2006-10-19 2013-08-14 武田薬品工業株式会社 インドール化合物
WO2008093639A1 (fr) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited Composé de pyrazole
KR20090106660A (ko) 2007-02-09 2009-10-09 다케다 야쿠힌 고교 가부시키가이샤 Ppar-감마의 부분 작용제로서의 축합 고리 화합물
EP2149550A4 (fr) 2007-04-27 2010-08-11 Takeda Pharmaceutical Composé hétérocyclique à cinq chaînons à teneur en azote
JP2011502958A (ja) 2007-06-19 2011-01-27 武田薬品工業株式会社 グルコキナーゼ活性化インダゾール化合物
JP2010229034A (ja) 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
KR101207830B1 (ko) 2008-06-19 2012-12-04 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물 및 그의 용도
JP4901849B2 (ja) 2008-12-15 2012-03-21 バブコック日立株式会社 空気清浄機、及び分析室、並びに空気の浄化方法
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity

Also Published As

Publication number Publication date
TN2012000589A1 (en) 2014-04-01
BR112012032055B1 (pt) 2019-10-22
BR112012032055B8 (pt) 2019-11-12
US20130252954A2 (en) 2013-09-26
MX2012014828A (es) 2013-02-27
WO2011158880A1 (fr) 2011-12-22
EP2583967B1 (fr) 2014-10-01
EA022094B1 (ru) 2015-10-30
CA2802483A1 (fr) 2011-12-22
JPWO2011158880A1 (ja) 2013-08-19
SG186223A1 (en) 2013-01-30
CA2802483C (fr) 2017-10-24
MY163927A (en) 2017-11-15
AU2011266099B2 (en) 2014-09-11
BR112012032055A2 (pt) 2016-11-08
US20130090337A1 (en) 2013-04-11
TW201206914A (en) 2012-02-16
CN103068816A (zh) 2013-04-24
ECSP13012392A (es) 2013-03-28
HK1179605A1 (en) 2013-10-04
JP5782438B2 (ja) 2015-09-24
CO6670573A2 (es) 2013-05-15
IL223562A (en) 2015-03-31
GEP20146195B (en) 2014-11-10
UA108888C2 (xx) 2015-06-25
KR20130119903A (ko) 2013-11-01
EP2583967A4 (fr) 2013-09-04
ZA201300065B (en) 2014-03-26
ES2524896T3 (es) 2014-12-15
DOP2012000313A (es) 2013-02-15
CN103068816B (zh) 2015-01-07
EA201291453A1 (ru) 2013-05-30
PH12012502468A1 (en) 2015-05-08
PE20130283A1 (es) 2013-03-25
TWI511967B (zh) 2015-12-11
EP2583967A1 (fr) 2013-04-24
CL2012003526A1 (es) 2013-05-31
US9018374B2 (en) 2015-04-28
AU2011266099A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
MA34378B1 (fr) Cristal de composé amide
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
MX356965B (es) Composiciones y metodos para profilaxis y tratamiento de adicciones.
PE20220766A1 (es) Agonistas de receptor de melanocortina-4
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
TW200626068A (en) Active compounds for seed treatment
BRPI0516575A (pt) composições fungicidas sinergìsticas
CA2725933A1 (fr) Combinaisons de medicaments comprenant un inhibiteur de dgat et un agoniste de ppar
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
MX2010001004A (es) Derivados de n-cicloalquil-bencil-tiocarboxamida o n-cicloalquil-bencil-amidina-n´-sustituida como fungicidas.
MA33071B1 (fr) Compose a noyau condenses et son utilisation
MX2010004232A (es) Compuesto de indolina de pirimidilo.
MX2009007668A (es) 1,3-dioxanos sustituidos y sus usos.
EP1861399A4 (fr) Antagonistes du recepteur du cgrp
PH12021552018A1 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
GEP20084519B (en) 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
JP2013518884A5 (fr)
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MX2009006359A (es) Derivados de aril sulfamida y metodos para su uso.
MY156965A (en) Plant disease control composition and its use
UA98757C2 (ru) Бензамидные соединения, полезные как ингибиторы деацетилазы гистонов
PE20051091A1 (es) N-ciclohexilimidazolinonas sustituidas y procedimientos para su preparacion
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MX2013002649A (es) Agente terapeutico contra el dolor.